Recent Quotes (30 days)

You have no recent quotes
chg | %

Spectral Medical Inc  

(Public, TSE:EDT)   Watch this stock  
Find more results for TSE:SDI
+0.02 (1.94%)
Apr 17 - Close
TSE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 1.00 - 1.07
52 week 0.26 - 1.18
Open 1.07
Vol / Avg. 193,297.00/534,715.00
Mkt cap 200.35M
P/E     -
Div/yield     -
EPS -0.06
Shares 190.81M
Beta 1.42
Inst. own     -
Mar 25, 2015
Q4 2014 Spectral Medical Inc Earnings Release

Key stats and ratios

Q4 (Dec '14) 2014
Net profit margin -265.24% -320.24%
Operating margin -360.94% -342.81%
EBITD margin - -334.08%
Return on average assets -57.98% -89.13%
Return on average equity -74.18% -130.78%
Employees 19 -
CDP Score - -


135-2 The West Mall
+1-416-6263233 (Phone)
+1-416-6267383 (Fax)

Website links


Spectral Medical Inc. (Spectral), formerly Spectral Diagnostics Inc., is focused on the development and commercialization of a treatment for severe sepsis. The Company�s products include Endotoxin Activity Assay (EAA) and the Toraymyxin therapeutic (PMX) and Reagents. The Company also manufactures and sells certain proprietary reagents. Endotoxin Activity Assay is a product approved by the United States Federal and Drug Administration (FDA), Health Canada and European CE clearance. PMX is a therapeutic hemoperfusion device that removes endotoxin from the bloodstream and the Company is conducting a Phase III clinical trial for the treatment of severe sepsis and septic shock. Spectral develops, produces and markets recombinant proteins, antibodies and calibrators.

Officers and directors

Anthony P. Bihl III Chairman of the Board
Age: 57
Paul M. Walker M.D., Ph.D. President, Chief Executive Officer, Director
Anthony Businskas Chief Financial Officer, Executive Vice President, Corporate Secretary
Guadagni Guadagni Vice President - Sales and Marketing
Debra M. Foster RN Vice President - Clinical Development
William Charles Stevens Director
Guillermo A. Herrera Independent Director